FDA accepts Novocure's PMA for TTFields in NSCLC post-platinum; decision H2 2024

NovoCure Ltd

PMA application accepted for filing; FDA begins substantive review.
Submission filed Dec 15, 2023; regulatory decision expected in second half 2024.
TTFields therapy plus standard systemic therapies for NSCLC after progression on platinum-based therapy.
CEO states milestone brings therapy closer to patients with few non-toxic options.
Application based on LUNAR trial data in post-platinum NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.